Beta-6-integrin in colorectal carcinoma: patho-functions and perspectives as a therapeutic target

结直肠癌中的 Beta-6 整合素：病理功能和作为治疗靶点的前景

• 批准号: 437201724
• 负责人: Professor Dr. Michael Stürzl
• 金额: --
• 依托单位: Klinik für Gastroenterologie und Hepatologie
• 依托单位国家: 德国
• 项目类别: Research Grants
• 资助国家: 德国
• 项目状态: 未结题
• 来源: https://gepris.dfg.de/gepris/projekt/437201724?language=en
• 关键词: Beta; integrin; colorectal; carcinoma; patho

Colorectal carcinoma (CRC) is one of the most challenging diseases world-wide, causing deaths of hundreds of thousands of people yearly. In our previous work we showed that ITGB6 expression and serum levels are increased in metastatic stages of CRC. Moreover, ITGB6 serum levels were found to be associated with therapy response and functional studies in CRC mouse models suggested that pharmacologic ITGB6 inhibition may counteract tumor growth. Here we aim to elucidate the role of ITGB6 as a pathogenic factor and therapeutic target in CRC. To achieve these goals we will apply state-of-the-art molecular approaches, novel ex vivo cell-based systems and in vivo mouse models. Translational validation of our results will be obtained using human samples obtained from large and clinically well-documented cohorts of CRC patients. The well-established co-operation and complimentary research expertise of the two project partners will highly foster the project success. The bi-national co-operation will (i) generate a high educational value for the employees involved, (ii) improve the understanding of CRC pathogenesis and (iii) provide novel avenues for treatment of this disease.

结直肠癌(CRC)是世界范围内最具挑战性的疾病之一，每年导致数十万人死亡。在我们以前的工作中，我们发现ITGB6的表达和血清水平在结直肠癌的转移期升高。此外，ITGB6血清水平被发现与治疗反应有关，在CRC小鼠模型中的功能研究表明，药物对ITGB6的抑制可能会抑制肿瘤的生长。在此，我们旨在阐明ITGB6在结直肠癌中作为致病因子和治疗靶点的作用。为了实现这些目标，我们将应用最先进的分子方法、新颖的体外细胞系统和体内小鼠模型。我们结果的翻译验证将使用从大量临床记录良好的CRC患者队列中获得的人类样本来获得。两个项目合作伙伴的良好合作和互补的研究专业知识将极大地促进项目的成功。这一国际合作将(I)为参与的员工创造高教育价值，(Ii)提高对CRC发病机制的了解，以及(Iii)为这种疾病的治疗提供新的途径。